Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TULIP SLE LTE long-term safety extension of anifrolumab in adults with active systemic lupus erythematosus
MOH_2017-03-19_000252Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of anifrolumab in systemic lupus erythematosus (SLE) (2 arms), sponsored by AstraZeneca. Started Oct 2016; status: completed.
02
Drugs
anifrolumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on MOH_2017-03-19_000252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-03-19_000252.